


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-2.89%
+17.99%
-2.55%
-6.15%
SCLX
Scilex Holding Company
$19.15
Strengths

Earnings are forecast to grow
SCLX Price Performance
$18.81 (+1.81%)
$25.36 (-24.49%)
$7 (+173.57%)
$0.46 (+4063.04%)
SCLX has Extreme risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

Low volume

High volatilty

SCLX overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
SCLX Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
SCLX Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels
Login to displayWhat is SCLX current stock price?
What are SCLX stock strengths?
What is SCLX Risk Level?
What is SCLX market cap and volume?
What is SCLX current Stock IQ?
Should I buy SCLX stock right now?
Is SCLX a Strong Buy right now?
What does a 'Strong Buy' rating mean for SCLX?
What does a 'Strong Sell' rating mean for SCLX?
What factors influence SCLX's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-2.89%
+17.99%
-2.55%
-6.15%
SCLX
Scilex Holding Company
Current Price
$19.15
Stock Insights
Strengths

Earnings are forecast to grow

SCLX Price Performance
$18.81 (+1.81%)
$25.36 (-24.49%)
$7 (+173.57%)
$0.46 (+4063.04%)
SCLX Analysts Opinion
SCLX Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
SCLX Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
SCLX Street Sentiment is extremely bullish and have positive views on the near-term outlook
SCLX has Extreme risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

Low volume

High volatilty

Average key support and resistance price levels
SCLX Stock IQ
SCLX Latest Analysis
Scilex Holding Company Announces Closing of Previously Announced Second Tranche Investment in Datavault AI Inc. Completing Its Two-Tranche Equity Financing in Datavault AI Inc.. PALO ALTO Calif. Nov. 26 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex or the Company) (Nasdaq: SCLX) an innovative revenue-generating company focused on acquiring developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometab
Wed Nov 26, 2025
Scilex Holding Company Announces Closing of Exercise of Warrants for $20.3 Million Gross Proceeds. PALO ALTO Calif. Nov. 25 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex or the Company) (Nasdaq: SCLX) an innovative revenue-generating company focused on acquiring developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease announced today the closing of its previously announced exercise o
Tue Nov 25, 2025
ORMP: Advancing Clinical Activities Generating Gains From Investment Portfolio New Rights Plan Adopted. By Trial will focus on key patient subpopulations that have responded to ORMD-0801 following analysis of earlier trial dataOramed Pharmaceuticals (NASDAQ:ORMP) is leveraging its balance sheet to make investments in multiple early stage companies while concurrently advancing its strategy to move its assets forward. Oramed plans to continue its oral insulin development program independently whic
Mon Nov 24, 2025
Scilex Holding Company Announces Exercise of Warrants for $20.3 Million Gross Proceeds. PALO ALTO Calif. Nov. 24 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex or the Company) (Nasdaq: SCLX) an innovative revenue-generating company focused on acquiring developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease announced today that it has entered into a definitive agreement for the exerc
Mon Nov 24, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
SCLX Stock trends
SCLX Stock performance
SCLX Stock analysis
SCLX investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.